NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
UMIN ID: C000000153

Registered date:10/09/2005

Study of imatinib monotherapy and combination of imatinib with IFN or cytarabine ocfosfate for chronic-phase CML (JALSG CML202 Study)

Basic Information

Recruitment status Complete: follow-up complete
Health condition(s) or Problem(s) studiedPreviously untreated chronic-phase chronic myelogenous leukemia
Date of first enrollment2002/04/01
Target sample size300
Countries of recruitmentJapan
Study typeInterventional
Intervention(s)Imatinib Imatinib+Interferon-alpha Imatinib+Cytarabine ocfosfate

Outcome(s)

Primary Outcome1) Imatinib monotherapy: overall survival 2) Combination therapy: cytogenetic response at 9 months
Secondary Outcome1) Imatinib monotherapy: toxicity, hematologic response at 6 months, cytogenetic response at 9 months, progression free survival, time to treatment failure 2) Combination therapy: toxicity, hematologic response, cytogenetic response, overall survival, progression free survival, time to treatment failure

Key inclusion & exclusion criteria

Age minimum15years-old
Age maximumNot applicable
GenderMale and Female
Include criteria
Exclude criteria1. Other active neoplasms 2. Severe comorbidity 3. Hypersensitivity to imatinib 4. Previously treated with IFN 5. Psychological disorders 6. Pregnant and/or lactating woman 7. CML in accelerated phase or blast crisis

Related Information

Contact

public contact
Name Kazunori Ohnishi
Address 1-20-1, Handayama, Higashi-ku, Hamamatsu, 431-3192, Japan Japan
Telephone 053-433-4993
E-mail jalsgsc@hama-med.ac.jp
Affiliation JALSG CML202 Study Office Hamamatsu University School of Medicine, Division of Clinical Oncology
scientific contact
Name Kazunori Ohnishi
Address 1-20-1, Handayama, Higashi-ku,Hamamatsu, 431-3192, Japan Japan
Telephone 053-433-4993
E-mail kohnishi@hama-med.ac.jp
Affiliation Hamamatsu University School of Medicine Division of Clinical Oncology